CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Total	Common Stock	Preferred Stock	Additional Paid-In Capital	Accumulated Deficit	Noncontrolling Interest
Balance, shares at Jun. 30, 2021		15,262,394	500,000
Balance, amount at Jun. 30, 2021	$ 21,217,973	$ 15,262	$ 500	$ 25,372,247	$ (4,170,036)	$ 0
Issuance of common stock for acquisition of Infusionz, shares		306,945
Issuance of common stock for acquisition of Infusionz, amount	1,764,876	$ 307	0	1,764,569	0	0
Issuance of common stock for acquisition of VitaMedica, shares		100,000
Issuance of common stock for acquisition of VitaMedica, amount	482,000	$ 100	0	481,900	0	0
Issuance of common stock for acquisition costs, shares		7,000
Issuance of common stock for acquisition costs, amount	33,740	$ 7	0	33,733	0	0
Stock based compensation	593,098	$ 0	0	593,098	0	0
Issuance of common stock for services, shares		35,000
Issuance of common stock for services, amount	175,000	$ 35	0	174,965	0	0
Net income for the three months ended September 30, 2021	511,711	$ 0	$ 0	0	511,711	0
Balance, shares at Sep. 30, 2021		15,711,339	500,000
Balance, amount at Sep. 30, 2021	24,778,398	$ 15,711	$ 500	28,420,512	(3,658,325)	0
Balance, shares at Jun. 30, 2022		16,713,345	500,000
Balance, amount at Jun. 30, 2022	28,786,744	$ 16,713	$ 500	34,985,597	(6,270,886)	54,820
Stock based compensation	927,326	0	0	927,326	0	0
Net income for the three months ended September 30, 2021	(2,745,520)	0	0	0	(2,597,515)	(148,005)
Amortization of common stock issuance for services	70,350	$ 0	$ 0	70,350	0	0
Balance, shares at Sep. 30, 2022		16,713,345	500,000
Balance, amount at Sep. 30, 2022	$ 27,038,900	$ 16,713	$ 500	$ 35,983,273	$ (8,868,401)	$ (93,185)